Additionally, in vitro ibrutinib treatment of naive vs treatment-relapsed CLL patient samples revealed an increase in both pten and foxo3a mRNA levels in treatment naive in contrast to relapsed patients (Fig. 3e and f). Here, FOXO3 is linked to B-cell chronic lymphocytic leukemia.